Dissemin is shutting down on January 1st, 2025

Published in

Springer Verlag, Journal of Neuro-Oncology, 2(104), p. 523-527

DOI: 10.1007/s11060-010-0504-2

Links

Tools

Export citation

Search in Google Scholar

Genetic variations in VEGF and VEGFR2 and glioblastoma outcome

Journal article published in 2010 by S. Sjöström, C. Wibom, U. Andersson, T. Brannstrom, T. Brännström, H. Broholm, C. Johansen ORCID, H. Collatz-Laier, Y. Liu, M. Bondy ORCID, R. Henriksson, B. Melin
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) are central components in the development and progression of glioblastoma. To investigate if genetic variation in VEGF and VEGFR2 is associated with glioblastoma prognosis, we examined blood samples from 154 glioblastoma cases collected in Sweden and Denmark between 2000 and 2004. Seventeen tagging single nucleotide polymorphisms (SNPs) in VEGF and 27 in VEGFR2 were genotyped and analysed, covering 90% of the genetic variability within the genes. In VEGF, we found no SNPs associated with survival. In VEGFR2, we found two SNPs significantly associated to survival, namely rs2071559 and rs12502008. However, these results are likely to be false positives due to multiple testing and could not be confirmed in a separate dataset. Overall, this study provides little evidence that VEGF and VEGFR2 polymorphisms are important for glioblastoma survival.